BMY.US Weekly Report · 2026-W35
FDA’s accelerated approval of Bristol Myers’ novel myeloma drug last week powered the stock to a 52-week high. This week, however, the initial gains reversed into a 0.64% decline by Friday as the rally faded. Q2 earnings surged 153% year-over-year, far exceeding consensus, and valuation sits at a historical low—yet institutional capital is retreating from this strength. The divergence between robust fundamentals and weakening fund flows suggests the market is digesting known catalysts while assessing limited upside.
Price Action
The stock closed Friday at $66.58, down 0.64% from August 21’s close of $67.01. Intraday range: $68.05 high to $66.19 low, yielding a 2.8% swing. Weekly volume totaled 55.44 million shares ($368.7M notional), marking a contraction relative to the 60-day median. The weekly pattern shows an opening thrust to $68 followed by a four-day pullback, characteristic of “rally exhaustion” rather than consolidation.
Valuation & Earnings
Current P/E of 14.65x is historically cheap—cheaper than approximately 61% of observations in the past five years. P/B stands at 6.09x. Market capitalization is $136 billion.
Q2 2026 EPS of $1.62 soared 153% YoY and 23% sequentially (Q1: $1.31). Operating revenue $12.97B (+5.74% YoY). Net income $3.32B (+153% YoY), with net margin at 25.57%. These figures demonstrate accelerating profit conversion.
Consensus EPS forecast (full-year) median $6.37, mean $6.42. The latest analyst target price of $66.21 (updated Aug 18) provides minimal upside from current levels, offering no meaningful price discovery.
Capital Flows & Institutional Views
Capital exhibits marked divergence: large funds net inflow +91.66, mid-tier net inflow +41.06, but retail small funds large outflow -334.05. Overall net outflow: -201. This structure explains the failure to sustain the rally—institutional enthusiasm is tempered.
Analyst consensus: 29 rating firms; 7 strong buy, 17 hold/accumulate, 1 neutral, 1 reduce. The bias is constructive, though ratings updated through Aug 18 are inherently backward-looking relative to this week’s price action. Retail outflows into strength suggest investors are locking in gains post-FDA approval.
Summary
Bristol Myers presents a classic divergence. Fundamentals are compelling: 153% EPS growth, valuation in the lower percentile, and analyst consensus is positive. Yet capital is flowing out, particularly retail exit, even as the stock trades at lows relative to historic multiples. This suggests the market is repricing the FDA approval from a “catalyst” discount to “baked into consensus” territory. The combination of cheap valuation and strong earnings provides downside cushion, but declining volume and fund outflows at resistance signal limited near-term upside absent fresh catalysts. Monitor Q3 guidance and pipeline news for the next inflection point.
Key News (This Week)
- Cytokinetics Scores A First-Ever In Its Rivalry Against Bristol Myers (Aug 28)
- BUZZ-Cytokinetics rises after heart disease drug shows promise in late-stage study (Aug 28)
- Bristol Myers ends blood cancer drug deal with cell therapy maker Cellares (Aug 23)
- Bristol Myers Confirms That They Have Ended Partnership With Cellares, Spokesperson Says (Aug 23)
- Bristol Myers Squibb hits 52-week high after FDA grants accelerated approval for myeloma drug (Aug 19)
- Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene (Aug 14)
- Zacks Research Brokers Increase Earnings Estimates for BMY (Aug 13)
- Wall Street’s Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields (Aug 22)
- Bristol-Myers Squibb Co Stock (BMY) Moved Up by 3.06% on Aug 21: Drivers Behind the Movement (Aug 21)
- Bristol-Myers Squibb Co Stock (BMY) Closed Down by 3.17% on Aug 20: Facts Behind the Movement (Aug 20)